VACH has the strength of having included more than 2000 treated patients with details concerning CVD risk factors, with an almost insignificant proportion of missing data.
← all excerpts
Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.
1
—
—